Zogenix, Inc., a prominent biopharmaceutical company headquartered in the United States, focuses on developing and commercialising innovative therapies for patients with rare neurological diseases. Founded in 2013, Zogenix has made significant strides in the industry, particularly with its flagship product, Fintepla, which is designed to treat Dravet syndrome, a severe form of epilepsy. With a commitment to addressing unmet medical needs, Zogenix operates primarily in the US and has expanded its reach to international markets. The company is recognised for its unique approach to drug development, leveraging advanced formulations to enhance patient outcomes. Zogenix's dedication to innovation and patient care has solidified its position as a leader in the biopharmaceutical sector, earning accolades for its contributions to the treatment of complex neurological disorders.
How does Zogenix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Zogenix, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zogenix, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Zogenix may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As such, the company does not inherit any emissions data from a parent organisation, nor does it participate in recognised climate frameworks like the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). Without specific emissions data or reduction commitments, Zogenix's climate impact remains unclear within the industry context.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zogenix, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.